2seventy: Nick Leschly brings a trio of top execs with him on top-speed flight from the bluebird nest
After serving more than a decade as bluebird bio’s chief bluebird, Nick Leschly is switching it up.
At some point this year, Leschly will officially become the CEO of 2seventy — the new company that will house bluebird’s oncology business while Andrew Obenshain, the current president for severe genetic diseases, will take over as CEO to oversee the rare disease pipeline remaining at bluebird.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,000+ biopharma pros reading Endpoints daily — and it's free.